[Prevention of morbus haemolyticus neonatorum and of transitory hyperbilirubinemias of newborn infants through an enzyme inductor combination].
D001663:Bilirubin / Q000097:blood; D004357:Drug Synergism; D004790:Enzyme Induction; D004899:Erythroblastosis, Fetal / Q000188:drug therapy*; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D005500:Follow-Up Studies; D014453:Glucuronosyltransferase / Q000096:biosynthesis; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007567:Jaundice, Neonatal / Q000188:drug therapy*; D009552:Nikethamide / Q000627:therapeutic use*; D009963:Orotic Acid / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use*; D011247:Pregnancy
D009552:Nikethamide; D009963:Orotic Acid; D014453:Glucuronosyltransferase; D001663:Bilirubin; D010634:Phenobarbital
Prophylaxe des Morbus haemolyticus neonatorum und transitorischer Hyperbilirubinämien von Neogeborenen durch eine Enzyminduktoren-Kombination.